Association between objective response rate and overall survival in metastatic neuroendocrine tumors treated with radioembolization: a systematic literature review and regression analysis
Sign Up to like & getrecommendations! Published in 2020 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2020.1814748
Abstract: ABSTRACT Objectives Neuroendocrine tumors (NETs) are a heterogeneous group of cancers arising from neuroendocrine cells. The aim was to evaluate objective response rate (ORR) as a predictor of overall survival (OS) in patients with metastatic… read more here.
Keywords: resin; objective response; neuroendocrine tumors; review ... See more keywords
Influence of pretreatment tumor growth rate on objective response of hepatocellular carcinoma treated with transarterial chemoembolization
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Gastroenterology and Hepatology"
DOI: 10.1111/jgh.14816
Abstract: The study aims to assess the influence of pretreatment tumor growth rate (TGR) on modified response evaluation criteria in solid tumors (mRECIST) objective response (OR) after a first session of selective transarterial chemoembolization (TACE) for… read more here.
Keywords: response; pretreatment tumor; influence pretreatment; objective response ... See more keywords
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
Sign Up to like & getrecommendations! Published in 2020 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2019-000146
Abstract: Background Response criteria developed when cytotoxic chemotherapy was the predominant therapeutic modality to treat patients with cancer, do not capture the full spectrum of tumor response patterns observed with anti-PD-1/PD-L1 antibody treatment. iRECIST was developed… read more here.
Keywords: irecist; anti antibody; response; recist ... See more keywords
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-0994
Abstract: Purpose: MET-deregulated NSCLC represents an urgent clinical need because of unfavorable prognosis and lack of specific therapies. Although recent studies have suggested a potential role for crizotinib in patients harboring MET amplification or exon 14… read more here.
Keywords: crizotinib; objective response; met deregulated; cancer ... See more keywords
Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Liver Cancer"
DOI: 10.1159/000492533
Abstract: The results of a clinical trial of lenvatinib were published in the Lancet earlier this year [1]. According to the results, the response rate was higher for lenvatinib than for any other known molecular targeted… read more here.
Keywords: response; treatment; molecular targeted; objective response ... See more keywords
Objective response and prolonged stable disease in refractory adrenocortical carcinoma treated with cabozantinib: An international case series and protocols of phase II clinical trials.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e16118
Abstract: e16118 Background: Median overall survival (OS) in advanced adrenocortical (ACC) is only 12-15 months. Previous clinical trials with oral multi-kinase inhibitors (MKI) were negative likely due to inadvertent drug interaction with mitotane. Objective: To investigate… read more here.
Keywords: response; objective response; mitotane; stable disease ... See more keywords
Objective response (OR) by mRECIST to predict overall survival (OS) in patients with hepatocellular carcinoma (HCC) treated with sorafenib in the SILIUS trial.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.4_suppl.534
Abstract: 534Background: In SILIUS (NCT01214343) trial, combination of sorafenib and hepatic arterial infusion chemotherapy did not significantly improve OS in patients with advanced HCC compared with sorafe... read more here.
Keywords: trial; response mrecist; mrecist predict; objective response ... See more keywords
Association of objective response by mRECIST with better overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with systemic therapies: A systematic review and meta-analysis of randomized controlled trials.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.4_suppl.586
Abstract: 586Background: EASL guidelines for management of HCC recommends assessing tumor response according to mRECIST at all stages of the disease (EASL guidelines, J Hep 2018). Several studies have report... read more here.
Keywords: hcc; response mrecist; response; objective response ... See more keywords